Results 341 to 350 of about 2,747,170 (398)

Spatiotemporal Regulation of STING Activity by Linear Ubiquitination Governs Antiviral Immunity

Advanced Science, EarlyView.
This study uncovers a spatiotemporal regulation of STING activity by linear ubiquitination in antiviral immunity. At the early stage of the infection, LUBAC promotes STING linear ubiquitination to drive its trafficking from the ER to the Golgi apparatus for activation.
Yong Zhang, Yesheng Fu, Lihua Qiang, Mengyuan Zhao, Zhe Lu, Zhuo Zhao, Guoping Chen, Zehui Lei, Qiyao Chai, Pupu Ge, Bingxi Li, Jing Wang, Cui Hua Liu, Lingqiang Zhang   +13 more
wiley   +1 more source

Metabolic and behavioral alterations associated with viral vector-mediated toxicity in the paraventricular hypothalamic nucleus. [PDF]

Biosci Rep
Savani R, Park E, Busannagari N, Lu Y, Kwon H, Wang L, Pang ZP.   +6 more
europepmc   +1 more source

A Phase‐Separated SR Protein Reprograms Host Pre‐mRNA Splicing to Enhance Disease Susceptibility

Advanced Science, EarlyView.
This study identifies SR30, a splicing factor, as a negative regulator of tomato immunity. During Phytophthora infestans infection, the elevated SR30 forms nuclear condensates to suppress the alternative splicing (AS) of defense‐related genes in a phase separation manner.
Dong Yan, Jie Huang, Fengqi Tian, Haidong Shu, Han Chen, Qian Peng, Hongwei Wu, Jianlong Zhao, Anireddy S. N. Reddy, Gang Li, Yuanchao Wang, Suomeng Dong   +11 more
wiley   +1 more source

Irisin Attenuates Pulmonary Vascular Remodeling in Pulmonary Arterial Hypertension via Ubiquitin‐Mediated Regulation of ENO1

Advanced Science, EarlyView.
Irisin is a crucial plasma biomarker and promising therapeutic target that reflects disease severity, pulmonary vascular remodeling status and clinical outcome in patients with pulmonary arterial hypertension (PAH). As a novel protective factor, irisin is downregulated in PAH. By ubiquitination, irisin promotes Enolase 1 degradation and suppresses cell
Na Sun, Yong‐Bing Wang, Jing Huang, Run‐Wei Deng, Hui‐Yu He, Lei Gao, Xuan Gao, You‐Li Fan, Yan Cong, Yao‐Lei Guo, Yi‐Qiang Chen, Gui‐Jia Wang, Shao‐Hong Fang, Xia Gu, Bo Yu, Bing‐Xiang Wu   +15 more
wiley   +1 more source

Phase I Trial of Viral Vector-Based Personalized Vaccination Elicits Robust Neoantigen-Specific Antitumor T-Cell Responses. [PDF]

Clin Cancer Res
D'Alise AM, Leoni G, Cotugno G, Siani L, Vitale R, Ruzza V, Garzia I, Antonucci L, Micarelli E, Venafra V, Gogov S, Capone A, Runswick S, Martin-Liberal J, Calvo E, Moreno V, Symeonides SN, Scarselli E, Bechter O.   +18 more
europepmc   +1 more source

Two Cases of Immune Thrombocytopenia (ITP) Related to Viral Vector Vaccination ChAdOx1-S (AstraZeneca) and a Good Response after Thrombopoietin Receptor Agonist (TPO-RA) Therapy. [PDF]

Hematol Rep
Salveridou K, Tzamalis T, Klaiber-Hakimi M, Haase S, Gröpper S, Giagounidis A.   +5 more
europepmc   +1 more source

Liter-scale manufacturing of shelf-stable plasmid DNA/PEI transfection particles for viral vector production. [PDF]

Mol Ther Methods Clin Dev
Hu Y, Eder BA, Lin J, Li S, Zhu Y, Wang TH, Guo T, Mao HQ.   +7 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Non-Viral Vector-Mediated Gene Therapy for ALS: Challenges and Future Perspectives.

Molecular Pharmaceutics, 2021
Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease, for which no effective treatment is yet available to either slow or terminate it.
Gayathri R Ediriweera, Liyu Chen, J. Yerbury, K. Thurecht, K. Vine   +4 more
semanticscholar   +1 more source